Investornewsbreaks Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) To Host CYB003 Topline Depression Study Review, Briefing

(MENAFN- Investor Brand Network) Cybin (NYSE American: CYBN) (NEO: CYBN)
is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that it will discuss its topline phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an R&D investor briefing. The review is slated to take place in New York City beginning at 10:00 a.m. ET on Thursday, Nov. 30, 2023, and feature a panel titled“Understanding the Current Treatment Landscape in Depression and Therapeutic Potential of Psychedelics in Mental Health.” Key opinion leaders to participate in the panel include Dr. Maurizio Fava, chair of the department of psychiatry/psychiatrist-in-chief of the Massachusetts General Hospital and Dr. Gitte M. Knudsen, chair of neurobiology research unit, Rigshospitalet and University of Copenhagen, Denmark. A live webcast of the event will be available on Cybin's
Investor Relations
website.

To view the full press release, visit

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to CYBN are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

InvestorWire
Los Angeles, CA

310.299.1717 Office

InvestorWire is powered by
IBN

MENAFN20112023000224011066ID1107459734